PEPTOKING
EN

FDA approves Wegovy pill, the first oral GLP-1 drug for weight loss

Approval

The FDA approved once-daily oral semaglutide 25 mg (Wegovy pill) for chronic weight management and to reduce the risk of major cardiovascular events, the first oral GLP-1 receptor agonist approved for obesity. In the OASIS 4 trial, average weight loss was about 14% versus about 2% on placebo regardless of adherence, and about 17% versus 3% among people who stayed on treatment. Novo Nordisk set a self-pay price of $149 a month for the 1.5 mg starting dose ahead of a January 2026 launch.

Sources

  1. 01FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults(opens the source in a new tab) Novo Nordisk via PR Newswire
  2. 02Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity(opens the source in a new tab) Fierce Pharma

Peptides involved

  1. ApprovedSemaglutideGLP-1 receptor agonist31